A novel type of influenza A virus-derived Defective interfering Particle for antiviral therapy
Forschungs-Reagenzien : Antikörper
Recent research indicates that defective interfering particles (DIPs) may also serve as antiviral agents. Conventional DIPs are particles containing a highly deleted form of the viral genome, which renders them non-infectious. The DIPs interfere with the standard virus by replicating at its expense in a co-infection scenario. As a result, mainly non-infectious DIPs are released by the cells. Furthermore, conventional DIPs have been shown to protect mice and ferrets from an otherwise lethal dose of IAV in several previous studies.
So far, DIPs have been primarily identified and characterized on the basis of their large genomic deletions. The present technology covers a novel DIP-type, termed OP7 virus, which contains 37 nucleotide substitutions in its genomic segment number 7 instead of deletions. Moreover, OP7 shows interference in vitro against relevant epidemic and pandemic strains, and interference in human cell lines. OP7 also shows a stronger inhibition of virus replication compared to conventional DIPs in vitro. Comparative animal studies in mice and in ferrets (conventional DIPs vs OP7) and studies regarding options for cell culture-based production of OP7 show encouraging preliminary results making OP7 viruses promising candidates for antiviral therapy.
- Influenza vaccines require two to three weeks for full protection; DIPs operate immediately.
- OP7 shows a stronger inhibition of virus replication compared to conventional DIPs.
- OP7 appears to interfere universally with different IAV strains. Thus, it may not need to be updated and produced again every season.
- Prophylactic treatment (a few weeks before infection) and therapeutic treatment (a few days after infection) are conceivable.
S. Kupke et al., Journal of Virology 2019 93 (4): e01786-18. doi: 10.1128/JVI.01786-18
Patent application number EP2018159908, filed on March 5th, 2018.
- Ref.-No.: 1402-5459-BC (445,1 KiB)
Dr. Bernd Ctortecka, M. Phil.
Senior Patent- & Lizenzmanager
Telefon: 089 / 29 09 19-20